Global Investors Cash Out
Under the deal, ImCheck shareholders — including Kurma Partners, EQT Life Sciences, and Pfizer — will receive the initial €350 million payout. French investors Eurazeo, Bpifrance, and Andera Partners are also among the beneficiaries, alongside Belgium’s Gimv Life Sciences and Germany’s Earlybird Venture Capital, Boehringer Ingelheim Venture Fund, Wellington Partners, and Pureos Bioventures.
From across the Atlantic, Pfizer Ventures, Invus, Agent Capital, Alexandria Venture Investments, and Blood Cancer United will exit their stakes in the French biotech after the acquisition closes.
Massive Returns for Early Backers
The deal marks a particularly lucrative exit for early investors. Gimv Life Sciences revealed it could see more than seven times its original investment if ImCheck achieves all outlined milestones. Meanwhile, Kurma Partners, which helped found ImCheck in 2015 and backed all subsequent funding rounds, called the deal a major validation of long-term biotech innovation in Europe.
Other investors, including EQT Life Sciences and Bpifrance, declined to disclose the size of their initial investments but expressed optimism about the deal’s global impact on cancer therapeutics.
